Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Am Health Drug Benefits
.
2015 Mar;8(Spec Feature):180-3.
Author
Lisa A Raedler
PMID:
26629287
PMCID:
PMC4665056
No abstract available